颈复康药业集团有限公司 manufactures and sells pharmaceutical products, including granules, capsules, and other forms. The company describes itself as catering to various health needs.

颈复康药业集团有限公司

哈药集团人民同泰医药股份有限公司 is a well-known pharmaceutical distribution company in China, primarily engaged in the retail and wholesale of pharmaceuticals, online pharmacy, and specialized hospitals.

哈药集团人民同泰医药股份有限公司

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

CanSino Biologics Inc.

CanSinoBIO is a biopharmaceutical company dedicated to providing global solutions for the prevention and treatment of infectious diseases through research & development, manufacturing and commercialization of vaccine products for human use.

康希诺生物

Tianjin CanSino Biotechnology Inc. | 624 followers on LinkedIn. Tianjin CanSino Biotech Inc. is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet medical needs by developing and marketing leading-edge, high quality vaccines for China and other emerging markets at affordable prices.

CanSino has established bacterial and cell/viral culture pilot facilities in compliance to the current GMP standard.

Metric
Company Name	颈复康药业集团有限公司	哈药集团人民同泰医药股份有限公司
Symbol
MSH ID	CN:COM:CDJFK	CN:COM:HYRMTT
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Pharmaceuticals	Pharmaceuticals
Country	CN	CN
Stage
Employee Count
Website	cdjfk.com.cn	hyrmtt.com.cn
LinkedIn	%E9%A2%88%E5%A4%8D%E5%BA%B7%E8%8D%AF%E4%B8%9A%E9%9B%86%E5%9B%A2%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

6185

COM:CANSINOTECH

康希诺生物

Last Close

29.15

22/11 08:08

Market Cap

6.49B

Beta: -

Volume Today

1.73M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue